The company said revenue for Q3 2026 rose to $5.5 billion, up 7.2%, and that Organic revenue growth* was 6.2%. Net income margin was 11.1%, Adjusted EBIT margin* was 16.6%, and diluted EPS was $1.36.

1. 01

   The company said revenue for Q3 2026 rose to $5.5 billion, up 7.2%, and that Organic revenue growth* was 6.2%. Net income margin was 11.1%, Adjusted EBIT margin* was 16.6%, and diluted EPS was $1.36.

2. 02

   The company said cash flow from operating activities was $907 million and Free cash flow* was $793 million for Q3, and both measures include a tariff refund of $55 million. Capital expenditures for Q3 were $114 million, and the company declared a quarterly dividend of $0.04 per share.

3. 03

   The company raised its full-year 2026 outlook, now calling for Organic revenue growth of about 4.0%, Adjusted EBIT margin of 15.5% to 15.7%, Adjusted EPS of $4.95 to $5.05, and Free cash flow of $1.6B or more. The prior Adjusted EPS outlook was $4.80 to $5.00.

4. 04

   The company said it plans to acquire SOFIE Biosciences from Trilantic North America in October 2026 for a cash purchase price of $945 million. It said the transaction is expected to close in the first half of 2027, subject to customary closing conditions, including regulatory approvals.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.